Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 10/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3631295 | 0.79 | SIGMAR1 (0.40) | SIGMAR1TSHR | |
| SCHEMBL21243266 | 0.77 | SIGMAR1 (0.47) | SIGMAR1TAAR1CYP2D6SLC18A2SLC6A2 | |
| SCHEMBL20357548 | 0.76 | SIGMAR1 (0.42) | SIGMAR1TAAR1SLC6A2MAOASLC6A4 | |
| SCHEMBL7870000 | 0.76 | SIGMAR1 (0.55) | SIGMAR1TAAR1CYP2D6SLC18A2SLC6A2 | |
| SCHEMBL23387949 | 0.75 | CYP2D6 (0.50) | SIGMAR1TAAR1CYP2D6SLC18A2SLC6A2 | |
| SCHEMBL20394559 | 0.75 | SIGMAR1 (0.53) | SIGMAR1TAAR1CYP2D6SLC18A2SLC6A2 | |
| SCHEMBL9545301 | 0.73 | NPC1 (0.44) | SIGMAR1CYP1A2TSHR | |
| Hydrochloric Acid SCHEMBL11525467 | 0.73 | TAAR1 (0.45) | SIGMAR1TAAR1CYP2D6SLC18A2CYP3A4 | |
| SCHEMBL19253832 | 0.72 | SIGMAR1 (0.44) | SIGMAR1CYP3A4 | |
| SCHEMBL5544627 | 0.71 | NPC1 (0.53) | TAAR1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025076226-A1 | FUSED HETEROCYCLES FOR TREATING NEURODEGENERATIVE DISEASES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-04-10 | — | — | WO | disclosed |
| WO-2024026484-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| EP-4204420-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MAGL INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2023-07-05 | — | — | EP | disclosed |
| US-20220363694-A1 | N-CYANO-7-AZANORBORNANE DERIVATIVES AND USES THEREOF | AMGEN INC. (US) | 2022-11-17 | — | — | US | disclosed |
| EP-4013756-A1 | MLL1 INHIBITORS AND ANTI-CANCER AGENTS | Novartis AG (CH) | 2022-06-22 | — | — | EP | disclosed |
| EP-3873530-A1 | THERAPEUTIC METHODS | Genevant Sciences GmbH (CH) | 2021-09-08 | — | — | EP | disclosed |
| WO-2021053617-A1 | MLL1 INHIBITORS AND ANTI-CANCER AGENTS | NOVARTIS AG (CH) | 2021-03-25 | — | — | WO | disclosed |
| EP-3610017-A2 | TARGETED COMPOSITIONS | Arbutus Biopharma Corporation (CA) | 2020-02-19 | — | — | EP | disclosed |
| US-RE47221-E1 | Tricyclic compounds | ABBVIE INC. (US) | 2019-02-05 | — | — | US | disclosed |
| WO-2018191278-A2 | TARGETED COMPOSITIONS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2018-10-18 | — | — | WO | disclosed |
| WO-2010135560-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-11-25 | — | — | WO | disclosed |
| EP-2148853-A1 | INSECTICIDAL ARYL PYRROLIDINES | BAYER CROPSCIENCE AG (DE) | 2010-02-03 | — | — | EP | disclosed |
| US-20090118284-A1 | Novel compounds that are ERK inhibitors | MERCK SHARP & DOHME LLC | 2009-05-07 | — | — | US | disclosed |
| US-20090118284-A1 | Novel compounds that are ERK inhibitors | MERCK SHARP & DOHME LLC | 2009-05-07 | — | — | US | disclosed |
| WO-2008128711-A1 | INSECTICIDAL ARYL PYRROLIDINES | BAYER CROPSCIENCE AG (DE) | 2008-10-30 | — | — | WO | disclosed |
| US-20070191604-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-08-16 | — | — | US | disclosed |
| US-20070191604-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-08-16 | — | — | US | disclosed |
| EP-1565436-A4 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORP (US) | 2007-07-18 | — | — | EP | disclosed |
| EP-1565436-A2 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2005-08-24 | — | — | EP | disclosed |
| WO-2004050024-A2 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118284-A1 | Novel compounds that are ERK inhibitors | MAPK1, MAPK4, MAPK10 | SIGMAR1 1543/4885TAAR1 2976/4885CYP2D6 720/4885 |
| US-20070191604-A1 | Novel compounds that are ERK inhibitors | MAPK1, MAPK4, MAPKAPK2 | SIGMAR1 1454/4885TAAR1 2868/4885CYP2D6 862/4885 |
| US-20220363694-A1 | N-CYANO-7-AZANORBORNANE DERIVATIVES AND USES THEREOF | CYP3A7, CYP51A1, NT5C3B | SIGMAR1 1641/4885TAAR1 2240/4885CYP2D6 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.